v3.25.2
Acquisitions - Preliminaty Purchase Price Allocation (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Jul. 02, 2024
Business Combination [Line Items]      
Goodwill $ 6,493.1 $ 6,478.9  
Human Immunology Biosciences      
Business Combination [Line Items]      
Cash and cash equivalents     $ 62.5
Intangible assets:     1,600.0
Prepaid expense and other assets(1)     1.4
Operating lease assets     1.2
Accounts payable     (1.1)
Accrued liabilities     (35.0)
Deferred tax liabilities     (309.3)
Operating lease liabilities     (1.2)
Total identifiable net assets     1,361.4
Goodwill     261.0
Total assets acquired and liabilities assumed     1,622.4
Adjustment, prepaid expense and other 0.4    
Deferred tax liability, measurement period adjustment 4.9    
Goodwill, measurement period adjustment 4.5    
Human Immunology Biosciences | In-process research and development      
Business Combination [Line Items]      
Intangible assets: $ 1,600.0 $ 1,600.0  
Human Immunology Biosciences | Other clinical programs      
Business Combination [Line Items]      
Intangible assets:     7.9
Human Immunology Biosciences | Felzartamab (IgAN)      
Business Combination [Line Items]      
Intangible assets:     920.0
Human Immunology Biosciences | Felzartamab (IgAN) | In-process research and development      
Business Combination [Line Items]      
Intangible assets:     920.0
Human Immunology Biosciences | Felzartamab (AMR)      
Business Combination [Line Items]      
Intangible assets:     450.0
Human Immunology Biosciences | Felzartamab (AMR) | In-process research and development      
Business Combination [Line Items]      
Intangible assets:     450.0
Human Immunology Biosciences | Felzartamab (PMN)      
Business Combination [Line Items]      
Intangible assets:     265.0
Human Immunology Biosciences | Felzartamab (PMN) | In-process research and development      
Business Combination [Line Items]      
Intangible assets:     $ 265.0